The Impact of Common Neuropsychiatric Conditions on Cognitive Function

Elena Beyzarov, PharmD
Published Online: Thursday, April 5, 2012
Follow Pharmacy_Times:

Pharmacy Times Office of Continuing Professional Education


The Impact of Common Neuropsychiatric Conditions on Cognitive Function

Elena Beyzarov, PharmD

Scientific Director

Pharmacy Times Office of Continuing Professional Education


Elena Beyzarov, PharmD, has no relevant affiliations or financial relationships to disclose related to this activity.

Judy V. Lum, MPA; Ann C. Lichti, CCMEP; and Donna Fausak of the Pharmacy Times Office of Continuing Professional Education have no relevant affiliations or financial relationships to disclose related to this activity.

Bea Riemschneider, Jennifer Barrio, and David Allikas of Pharmacy Times Editorial have no relevant affiliations or financial relationships to disclose related to this activity.


Educational Objectives

Upon completion of this educational activity, participants should be able to:

  1. Examine the impact of schizophrenia, multiple sclerosis (MS), and Parkinson's disease (PD) on cognitive function.
  2. Understand the prevalence and pathophysiology of cognitive impairment in schizophrenia, MS, and PD.
  3. Evaluate evolving strategies aimed at minimizing neurodegeneration in schizophrenia, MS, and PD.
  4. Discuss the implications for the pharmacist in regard to identifying and counseling patients with cognitive impairment.

Target audience: Pharmacists

Type of activity: Knowledge

Release date: March 15, 2012

Expiration date: March 15, 2014

Estimated time to complete activity: 2 hours

Fee: This lesson is free online

Click here to view this activity.



Related Articles
Gedeon Richter and Actavis today announced positive results from a phase 3 trial evaluating the efficacy and safety of cariprazine, an investigational atypical antipsychotic, in preventing relapse among schizophrenia patients.
Janssen announced today that the FDA has granted Priority Review designation to its New Drug Application (NDA) for paliperidone palmitate, a 3-month atypical antipsychotic for treating schizophrenia in adults.
The FDA has acknowledged receipt of Actavis’s resubmitted New Drug Application for its investigational atypical antipsychotic, cariprazine, which is indicated for the treatment of patients with schizophrenia and manic or mixed episodes associated with bipolar I disorder.
A certain hormone could be linked to obesity, and that hormone just happens to be serotonin.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$